Stockwinners Market Radar for April 25, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:55 EDT Rockwell Automation, Doosan to partner on automation solutions - Rockwell Automation signed a Memorandum of Understanding to form a partnership with leading global robot manufacturer Doosan Robotics and its parent company Doosan Corporation. Rockwell and Doosan agreed to focus on further integrating the companies' robots and controllers, as well as developing robotic and other technologies for automation facilities, smart factory construction, and other applications for their customers globally. Doosan Robotics will become a long-term robot supplier for Rockwell's manufacturing operations, while Rockwell will provide automation solutions for Doosan, a holding company offering a wide range of products around the world.

20:31 EDT Cathie Wood's ARK Investment bought 583K shares of Invitae today

19:15 EDT PacWest Bancorp jumps 13% afterhours following Q1 earnings beat

18:34 EDT WeTrade receives non-compliance notice from Nasdaq - WeTrade Group announced that the company received from Nasdaq a notice of noncompliance because the company failed to timely file its 2022 annual report on form 10-K with the Securities Exchange Commission. Under Nasdaq rules, the company has 60 calendar days from receipt of the Notice or until June 20, 2023, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the company's plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the form 10-K, or until October 16, 2023, to regain compliance. The application has no immediate impact on the listing of the company's common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the company' s compliance with the other listing requirements of The Nasdaq Capital Market. The company is in the process of preparing the plan to regain compliance and finalizing the financial statements for the year ending December 31, 2022. The company will submit the plan to regain compliance and the 2022 annual report at soon as possible.

18:15 EDT Rambus CEO sells $617.7K in common stock - In a regulatory filing, Rambus disclosed that its CEO Luc Seraphin sold 12.5K shares of common stock on April 24th in a total transaction size of $617.7K.

18:08 EDT Microsoft sees Q4 commercial bookings 'relatively flat' - Says FX to cut Q4 revenue growth by 2%. Sees Q4: Intelligent Cloud revenue $23.6B-$23.9B; More Personal Computing revenue $13.35B-$13.75B; Productivity and Business Processes revenue $17.9B-$18.2B. Expects COGS to grow 3%-4%. Expects to scale up CapEx in FY24 for AI.

17:56 EDT Invesco boosts quarterly dividend 7% to 20c per share - The company is announcing a first quarter cash dividend of 20c per share to holders of common shares, an increase of 7%. The dividend is payable on June 2 to common shareholders of record at the close of business on May 9, with an ex-dividend date of May 8.

17:50 EDT Nuscale Power enters MOU with Doosan Enerbility for SMR deployment - NuScale Power announced it has signed an memorandum of understanding, or MOU, with Doosan Enerbility and export-import bank of Korea to strengthen collaboration among the three parties and support NuScale's small modular reactor, or SMR, deployment. This announcement leverages and bolsters an existing relationship between NuScale and Doosan, and it highlights the domestic and global manufacturing opportunities to build SMRs around the world.

17:49 EDT Alphabet says meaningfully slowing the pace of hiring - Says search is performing well and has momentum in cloud. Says cloud delivered profitability. Says lots more to come for Bard. Says saw stabilization in YouTube ads. Says other revenues were led by strong growth in YouTube subscriptions. Says meaningfully slowing the pace of hiring in FY23. Says expects FY23 capital expenditures to be modestly higher than FY22. Comments taken from Q1 earnings conference call.

17:26 EDT MRC Global comments on lawsuit filed by Mario Investments - MRC Global commented on a lawsuit filed by Mario Investments, an affiliate of Cornell Capital, the sole holder of MRC Global's 6.50% Series A Convertible Perpetual Preferred Stock. The lawsuit, brought against the company in the Delaware Court of Chancery, attempts to prevent MRC Global from moving forward with its previously announced refinancing of its senior secured Term Loan B. The company disputes Cornell Capital's claim in the lawsuit that Cornell Capital has a right to consent to the refinancing. The company made a statement: ""In light of the lawsuit filed by Cornell, we are currently evaluating options that will allow us to proceed in a manner that is in the best interest of all stockholders. While the company reviews these options, we are continuing to proceed with the previously announced effort to refinance in full our $295 million in outstanding principal amount under our existing senior secured Term Loan B. MRC Global will make updates to the market as more information is available in due course. Although we are seeking a refinancing of the Term Loan B now, it does not mature until September 2024. As of December 31, 2022, the company had availability under the company's asset-based lending facility of $606M yielding total liquidity, including cash on hand, of $638M. The company expects to generate $120M in cash from operations during 2023. Even though the company believes it has sufficient liquidity from these sources to ultimately discharge the balance of the Term Loan B, the company is pursuing the refinancing to take advantage of current market conditions, which the company believes are relatively favorable for a refinancing."

17:23 EDT Omnicom CEO sells $9.38M in common stock - In a regulatory filing, Omnicom disclosed that its CEO John Wren sold 100K shares of common stock on April 24th in a total transaction size of $9.38M.

17:16 EDT Digital World Acquisition discloses listing compliance notice from Nasdaq - Digital World Acquisition announced that it received an expected letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 10-K for the period ended December 31, 2022 with the Securities and Exchange Commission. The Nasdaq notification letter has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Stock Market.

17:03 EDT West Fraser Timber affirms FY23 capex of $500M-$600M - The company states: "We expect total lumber shipments in 2023 to be similar to 2022 levels as the transportation challenges that we faced last year are not expected to be as severe in 2023, offset by relative year-over-year softness in new home construction demand, the permanent B.C. mill curtailments announced in August 2022 and the indefinite curtailment of the Perry, Florida sawmill announced in January 2023. As such, we reiterate 2023 SPF shipments guidance of 2.6 to 2.8 billion board feet, and in the U.S. South, we reiterate 2023 SYP shipments guidance of 2.9 to 3.1 billion board feet. In our NA EWP segment, we expect 2023 OSB shipments to be similar to 2022 levels and reiterate shipments guidance of 5.9 to 6.2 billion square feet (3/8-inch basis) this year. Our modernization capital investment in Allendale, SC is nearing completion and we remain on track for a potential restart of the mill by the end of Q2-23. We anticipate a ramp-up period of up to three years to meet targeted production and as such we do not anticipate the Allendale mill contributing materially to shipments in 2023. In our Europe EWP segment, we reiterate 2023 OSB shipments guidance of 1.0 to 1.2 billion square feet (3/8-inch basis), moderately above 2022 levels, as demand markets stabilize. Pulp & Paper segment shipments are not expected to increase from 2022 levels this year as near-term supply and demand fundamentals are challenging. Recent demand weakness in China coupled with conversion of Russian NBSK pulp capacity to UKP has led to current oversupply conditions. In Q1-23, we experienced a moderation of costs and improved availability for inputs across our supply chain, including resins, chemicals, transportation and energy, although labour availability remained challenging. We expect these trends to continue over the near term. Based on our current outlook, assuming no deterioration from current market demand conditions during the year and that there is no additional lengthening of lead times for projects underway or planned, we reiterate our guidance of investing approximately $500 million to $600 million in expected capital expenditure in 2023."

16:55 EDT Bed Bath & Beyond receives Nasdaq delisting notice, cancels shareholder meeting - Bed Bath & Beyond announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market that Nasdaq had determined to delist the company's common stock as a result of the company's commencement of voluntary proceedings under Chapter 11 of the United States Bankruptcy Code. Nasdaq informed the company that trading in the company's common stock would be suspended at the opening of business on May 3. Additionally, the company is also announcing the cancellation of its previously announced Special Meeting of Shareholders that was scheduled for May 9. The company is also withdrawing from consideration all proposals set forth in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 5. Bed Bath & Beyond and certain of its subsidiaries filed for voluntary Chapter 11 protection on April 23.

16:49 EDT Carrier Global to acquire Viessmann Climate Solutions for EUR12B in cash, stock

16:42 EDT Enphase Energy falls 15% after below-consensus revenue for Q1 and Q2 forecast

16:37 EDT Alarm acquires substantially all assets of Vintra, terms not disclosed - Alarm.com announced the acquisition of substantially all assets of Vintra, a software provider of award-winning AI-powered video analytics for the enterprise commercial market. Integrating Vintra's software capabilities and its experienced science and engineering teams will expand Alarm.com's deep learning program and accelerate deployment of advanced video analytics solutions for the Alarm.com and OpenEye platforms. "The Vintra team adds to Alarm.com's science and engineering expertise in the field of AI and machine learning, and we're excited to welcome them on board," said Jeff Bedell, Alarm.com's President of Ventures Business and Corporate Strategy. "The acquisition expands the specialization of Alarm.com's AI team and will extend our leadership in this important domain. Our goal is to deploy market-defining video analytics solutions, scale them across the Alarm.com and OpenEye platforms, and open new areas of growth for our service provider and integrator partners." Alarm.com acquired Vintra's core intellectual property, its research scientists, software engineers, and technical services teams as part of the acquisition. Financial details of the transaction were not disclosed at the time of closing.

16:34 EDT Quanterix says Toferson results provide support for FDA's accelerated approval - Quanterix announced that blood-based NfL measurements provided compelling support for the FDA's accelerated approval of tofersen for treatment of superoxide dismutase 1 amyotrophic lateral sclerosis, a devastating rare genetic form of ALS. This is the first known case in which a blood biomarker was successfully used as a surrogate endpoint for a neurology therapeutic trial to gain accelerated approval, highlighting the potential for other therapeutic trial designs to benefit from including blood NfL measurements. Tofersen is designed to reduce the overproduction of SOD1 protein in SOD1-ALS patients. In the Phase III VALOR trial, the drug did not significantly slow patients' clinical decline. However, there were positive trends in the data, and open label extension results have since shown evidence of clinical benefits along with highly significant reductions of secondary endpoint biomarkers in favor of a positive treatment effect. This data supported an extended FDA review of tofersen's new drug application under the accelerated pathway leading to its recent announcement of approval. Critical to the approval were plasma NfL trends, with the FDA Advisory Committee voting unanimously that the "reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict clinical benefit of tofersen for treatment of patients with SOD1-ALS." Tofersen was found to lower plasma NfL levels 40-50 percent over a six-month period.

16:33 EDT Medtronic: FDA lifts warning letter received at company's Diabetes headquarters - Medtronic announced that the U.S. FDA lifted the warning letter received at the company's Diabetes headquarters in Northridge, California, in December 2021. This follows on the heels of last week's FDA approval of the MiniMed 780G system, the world's first and only automated insulin delivery system with meal detection technology that provides automatic adjustments and corrections to glucose levels every 5 minutes. The resolution of the warning letter follows ongoing remediation actions from the company and proactive actions to continue to strengthen its quality systems. All regulatory restrictions associated with the warning letter have been resolved.

16:31 EDT InfuSystem announces distribution agreement with Genadyne - InfuSystem announced a national distribution agreement with Genadyne Biotechnologies Inc. for its negative pressure wound therapy systems and supplies. InfuSystem will offer Genadyne's complete line of wound care products, including its most advanced XLR8 Plus NPWT Pump, which delivers advanced variable pressure capabilities with a gradual wave, in conjunction with Genadyne's proprietary XLR8 Dressing Kit with Silver, an antimicrobial contact layer to protect the wound.

16:30 EDT Viveon Health Acquisition receives noncompliance letter from NYSE - Viveon Health Acquisition announced that the company received a notice letter from the NYSE Regulation Department of the New York Stock Exchange American notifying the company that, based upon the company's failure to timely file its annual report on Form 10-K for the fiscal year ended December 31, 2022, it was not in compliance with the NYSE American's continued listing requirements. Pursuant to the notice, the company has six months, to file its annual report in order to reinstate its compliance with the applicable NYSE American listing standards.

16:28 EDT Churchill Downs announces two-for-one stock split - Churchill Downs announced that its the board of directors approved a two-for-one stock split. The stock split will be effectuated by distributing to each shareholder one additional share for every outstanding share held as of May 5. The company expects the additional shares to be distributed on May 19 and the stock to begin trading at the split-adjusted price starting on May 22.

16:21 EDT Nelnet awarded contract by the U.S. Department of Education Office of FSA - Nelnet announced its Nelnet Diversified Services division has been awarded a Unified Servicing and Data Solution, or USDS, contract by the U.S. Department of Education Office of Federal Student Aid, or FSA. The 5-year federal contract, with possible extensions up to 10 years, will replace existing legacy student loan servicing contracts for Direct Loans and federally managed Federal Family Education Loan, or FFEL, Program loans and will be centered on providing superior customer service to federal student loan borrowers through measurable service-level agreements and performance metrics. No immediate changes will impact student loan borrowers as the full terms of the agreement are expected to go live in 2024. According to the Department, the legacy servicer contracts will be extended through December 2024 to help facilitate a smooth transition for borrowers.

16:20 EDT Crestwood Equity CAO Dougherty to leave company - Crestwood Equity Partners LP announced that Steven Dougherty, Executive Vice President and Chief Accounting Officer, will be leaving the Company to pursue other opportunities. Mr. Dougherty will continue to serve in his current role through the end of the second quarter 2023 to ensure an orderly transition of his responsibilities. "I would like to personally thank Steven, or "Doc" as we fondly refer to him within the Company, for his many years of service and leadership at Crestwood. Doc has played a key role in building Crestwood from its infancy to what it is today, and his contributions have been fundamental to the Company's success," commented Robert G. Phillips, Founder, Chairman, and Chief Executive Officer of Crestwood. "Doc has been a core member of the Crestwood management team since 2012 and has developed a tremendous team of professionals within our accounting, financial reporting, tax, internal audit, IT, and risk management functions. We are excited for the opportunity for many of these highly talented leaders to advance their careers and are confident they are well prepared to ensure a seamless transition. While we are sad to see Doc move on from Crestwood, we wish him all the best in his future endeavors and the next chapter in his life." Dougherty will continue to serve as Executive Vice President and Chief Accounting Officer through the end of the second quarter 2023. Upon his departure, Jeff Cathey, Senior Vice President and Controller, will oversee the accounting department. Deana Werkowitch, Senior Vice President of Audit, Technology and Implementation Services will oversee the internal audit and technology functions. Donna Schmidt, Vice President of Tax will oversee the tax department. Casey Rosengarten, Vice President of Risk Management will oversee the risk management function.

16:19 EDT Enova International CEO sees growth on top, bottom line in 2023 vs. 2022 - "We delivered another quarter of solid top- and bottom-line results, with our balanced approach to growth enabling us to successfully navigate the current macroeconomic backdrop," said David Fisher, Enova's CEO. "The powerful combination of our flexible online-only business model, talented team, diversified product offerings and machine learning-powered credit risk management capabilities have enabled us to deliver consistent and differentiated results. We continue to produce industry-leading performance and based on what we are seeing in the current market environment, we continue to expect growth on both our top and bottom line in 2023 compared to 2022."

16:17 EDT Matador reports Q1 average production of 106,654 BOE per day

16:16 EDT MetLife raises quarterly dividend by 4% to 52c per share - The dividend will be payable on June 14, 2023, to shareholders of record as of May 9, 2023.

16:11 EDT Chipotle sees Q2 comparable restaurant sales growth mid to high-single digits - For 2023, management is anticipating the following: Second quarter and full year comparable restaurant sales growth in the mid to high-single digit range; 255 to 285 new restaurant openings (including 10 to 15 relocations to add a Chipotlane), which assumes utility, construction, permit and material supply delays do not worsen. An estimated underlying effective full year tax rate between 25% and 27% before discrete items.

16:10 EDT Virgin Galactic names Evan Lovell chair of the board - Virgin Galactic announced several changes to Virgin Galactic's Board of Directors including the appointment of two new directors. The company also announced that Virgin Group's Chief Investment Officer, Evan Lovell, has been appointed Chair of the Board of Directors, effective April 21. Lovell has served as the company's interim chair since February 2022 and as a member of the company's Board since October 2019. He is a seasoned private equity investor and operator, having invested and participated in global private equity and M&A over the past 20 years. The company also appointed two new directors: Raymond Mabus, Jr. and Diana Strandberg, with Mabus serving as Virgin Galactic's Lead Independent Director. Mabus brings extensive public sector experience to the role having served as U.S. Secretary of the Navy from 2009 to 2017 and as the Governor of Mississippi. Strandberg recently retired from a distinguished career at global investment manager, Dodge & Cox, most recently holding the role of Senior Vice President and Director, International Equity and as an Executive Board Member.

16:09 EDT Allison Transmission, Foton partner over compressed natgas buses to Nuevo Leon - Through its partnership with Foton, an international commercial vehicle manufacturer headquartered in Beijing, China, Allison Transmission is providing the propulsion solution for 400 Foton AUV compressed natural gas buses being exported to Nuevo Leon, Mexico, to aid in the state's plan to modernize public transportation. In China last year, Allison realized double digit growth in export bus sales. "This latest award is representative of the significant growth Allison is experiencing in the Chinese transit bus market as a result of partnerships we've established with OEMs to export buses from China to markets throughout the Americas, Asia, Oceania and the Middle East," said Heidi Schutte, Vice President of EMEA, APAC and South America Sales, Allison Transmission. "We're proud to collaborate with Foton to support Nuevo Leon in its efforts to improve quality of life for transit passengers by providing a cleaner transportation option that will support sustainability initiatives."

16:08 EDT Alphabet says board authorized added $70B in stock repurchases - Alphabet says: "On April 19, 2023, the Board of Directors of Alphabet authorized the company to repurchase up to an additional $70.0B of its Class A and Class C shares in a manner deemed in the best interest of the company and its stockholders, taking into account the economic cost and prevailing market conditions, including the relative trading prices and volumes of the Class A and Class C shares. The repurchases are expected to be executed from time to time, subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans."

16:08 EDT Hawaiian lowers FY23 economic fuel price per gallon view from $2.92 to $2.70 - Raises FY23 gallons of jet fuel consumed view to from 10.5%-13.5% to up 12.5%-15.5%.

16:06 EDT American Water rate settlement case gets approval from Virginia SCC - The Virginia State Corporation Commission, SCC, issued an order today approving a settlement that adjusts rates for Virginia American Water following a November 2021 rate change request. The request was driven by approximately $137.6 million in completed or planned infrastructure improvements. These improvements include replacement of aging pipe, water treatment plant upgrades and system resiliency projects that will help Virginia American Water continue the provision of clean, safe and reliable service for customers throughout the state. The rate order approves an overall increase in rates of approximately $10.75 million as reflected in the settlement agreement. The new rates are for the company's residential, commercial and industrial customers in the City of Alexandria, the City of Hopewell, a portion of Prince George County in the Hopewell District, a portion of Prince William County, and the Eastern District service area in and around Virginia's Northern Neck.

16:06 EDT Otis Worldwide raises quarterly dividend 17.2% to 34c per share - The dividend will be payable on June 9 to shareholders of record at the close of business on May 19.

16:05 EDT Alphabet CFO cites 'resilience in Search and momentum in Cloud' - Ruth Porat, CFO of Alphabet and Google, said: "Resilience in Search and momentum in Cloud resulted in Q1 consolidated revenues of $69.8 billion, up 3% year over year, or up 6% in constant currency. We remain committed to delivering long-term growth and creating capacity to invest in our most compelling growth areas by re-engineering our cost base."

16:03 EDT Texas Instruments says weakness across end markets with the exception of auto - Regarding the company's performance and returns to shareholders, Haviv Ilan, TI's president and CEO, made the following comments: "Revenue decreased 6% sequentially and decreased 11% from the same quarter a year ago. During the quarter we experienced weakness across our end markets with the exception of automotive, as expected. Our cash flow from operations of $7.7 billion for the trailing 12 months again underscored the strength of our business model. Free cash flow for the same period was $4.4 billion and 23% of revenue. This reflects the quality of our product portfolio, as well as the efficiency of our manufacturing strategy, including the benefit of 300-mm production. Over the past 12 months we invested $3.5 billion in R&D and SG&A, invested $3.3 billion in capital expenditures and returned $7.5 billion to owners. TI's second quarter outlook is for revenue in the range of $4.17 billion to $4.53 billion and earnings per share between $1.62 and $1.88. We continue to expect our 2023 effective tax rate to be about 13% to 14%."

16:01 EDT Evergy files rate review request with Kansas Corporation Commission - Evergy has filed a request and supporting documentation with the Kansas Corporation Commission to recover investments made to improve service to customers with a more reliable and resilient power grid and updated customer service systems. This is the first base rate review Evergy has requested in five years. Evergy was formed in 2018 by the merger of Westar Energy and Great Plains Energy. As part of the merger approval, Evergy agreed to keep the energy company local by maintaining its Kansas headquarters in Topeka and continuing to invest millions annually in local community organizations and charities throughout its Kansas service area. Evergy also committed to significantly reduce the operating costs of the combined company, to pass those savings on to customers and not to ask for an increase to base rates for five years. Evergy has kept all of those commitments. For the Evergy Kansas Central service area, the company is requesting a net revenue increase of $204 million or a 9.77% overall rate increase - reflecting a reduction of nearly $89 million in operating costs and other billing line items. If the full request is approved, the monthly bill increase for an average residential customer would be about $14.24. Evergy Kansas Central includes approximately 736,000 customers in Topeka, Pittsburg, Wichita, Hutchinson and other communities in the eastern third of the state. In the Evergy Kansas Metro service area, the company is requesting a net revenue increase of $14 million or a 1.95% overall rate increase - reflecting a reduction of nearly $41 million in operating costs and other billing line items. If the full request is approved, the monthly bill increase for an average residential customer would be about $3.47. Evergy Kansas Metro includes approximately 273,000 customers in Lenexa, Overland Park and other communities near the Kansas City metro area.

15:10 EDT Roche announces Vabysmo data suggests greater retinal drying vs. aflibercept - Roche announced that post-hoc data indicate treatment with Vabysmo led to greater and faster drying of retinal fluid with fewer injections compared to aflibercept in neovascular or 'wet' age-related macular degeneration, or nAMD. In diabetic macular edema, or DME, post-hoc data suggest Vabysmo treatment resulted in faster drying with fewer injections as well as less blood vessel leakage in the macula, the center of the retina, compared to aflibercept. The analyses from the phase III TENAYA and LUCERNE, or nAMD, and YOSEMITE and RHINE, or DME, studies were shared at the 2023 Association for Research in Vision and Ophthalmology, or ARVO, annual meeting, held from 23-27 April in New Orleans, United States. Vabysmo is the first bispecific antibody for the eye and is currently approved in 60 countries to treat nAMD and DME, with more than 800,000 Vabysmo doses distributed globally. A post-hoc analysis of pooled data from the head-to-head dosing period of the phase III TENAYA and LUCERNE studies in nAMD showed: Vabysmo reduced retinal fluid from baseline compared to aflibercept, as measured by reduction in central subfield thickness, or CST. At 12 weeks, CST reductions were 145 microm in the Vabysmo arm and 133 microm in the aflibercept arm. A larger proportion of Vabysmo patients had absence of retinal fluid at 12 weeks versus aflibercept, as measured by subretinal and intraretinal fluid. Absence of retinal fluid, as measured by absence of SRF and IRF observed in 75% of patients in each treatment arm, occurred at eight weeks with Vabysmo versus 12 weeks with aflibercept, corresponding to a fewer number of injections for Vabysmo patients versus aflibercept. A post-hoc analysis of pooled two-year data from the phase III YOSEMITE and RHINE studies in DME compared time to fluid control between Vabysmo and aflibercept, as measured by absence of DME and absence of IRF. The analysis showed: Absence of DME, defined as CST less than325 microm observed in 75% of patients in each treatment arm, occurred at 20 weeks with Vabysmo versus 36 weeks with aflibercept - a difference of nearly four months. Absence of retinal fluid, as measured by absence of IRF observed in 50% of patients in each treatment arm, occurred more than eight months earlier in Vabysmo patients versus aflibercept. Absence of IRF occurred at 48 weeks with Vabysmo versus 84 weeks with aflibercept, corresponding to a fewer number of injections for Vabysmo patients versus aflibercept. A separate post-hoc analysis of pooled data from the head-to-head dosing period of the YOSEMITE and RHINE studies evaluated blood vessel leakage in the macula - an important marker of vascular stability. Blood vessel leakage in the macula may lead to more retinal fluid, which can cause swelling and blurry vision.11 Results showed: The macular leakage area in Vabysmo patients was more than 50% smaller compared to aflibercept at 16 weeks. Vabysmo reduced the macular leakage area to 3.6 mm2 from baseline compared to 7.6 mm2 with aflibercept. Nearly twice as many patients had resolution of leakage versus aflibercept at 16 weeks.

15:08 EDT Biogen confirms FDA grants accelerated approval for Qalsody - Biogen (BIIB) announced that the U.S. Food and Drug Administration has approved Qalsody 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis, or ALS, in adults who have a mutation in the superoxide dismutase 1, or SOD1, gene. "This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain observed in patients treated with Qalsody. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). The ongoing Phase 3 ATLAS study of tofersen in people with presymptomatic SOD1-ALS will serve as the confirmatory trial," the company stated. Biogen collaborated with Ionis Pharmaceuticals (IONS) on the early development of tofersen. "Qalsody will be made available for shipment in the U.S. to healthcare providers in approximately one week. Biogen anticipates there may be variation in time to treatment as institutions and treatment centers learn about Qalsody," the company added.

14:33 EDT Akebia receives European Commission approval for Vafseo - Akebia Therapeutics announced that the European Commission has granted marketing authorisation for Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis. The approval is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein. Vadadustat is now approved in 32 countries. "We're extremely pleased the EC has approved Vafseo, an important milestone for Akebia but even more impactful for the hundreds of thousands of Europeans diagnosed with anaemia associated with CKD on dialysis," said John P. Butler, Chief Executive Officer of Akebia. "We believe patients receiving chronic maintenance dialysis would benefit from additional therapeutic options. With approval, we're eager to select a European partner who can quickly bring Vafseo to those patients."

14:05 EDT Voyager Digital says Binance.US terminating asset purchase agreement - Voyager Digital tweeted from its official Twitter account: "Today we received a letter from Binance.US terminating the asset purchase agreement. While this development is disappointing, our chapter 11 plan allows for direct distribution of cash and crypto to customers (a "toggle option") via the Voyager platform. [...] Consistent with the plan, we will now move swiftly to return value to customers via direct distributions. We will provide more information on next steps and any actions customers need to take in the coming days." Reference Link

13:48 EDT Cerevel holder Perceptive amends filing, says not in 'strategic' deal talks - Perceptive Advisors, which previously disclosed a 6.4% stake in Cerevel Therapeutics on April 21, has amended its filing "solely to amend and restate Item 4 of the Schedule 13D." The amended Item 4 of the the Schedule 13D states in part: "Perceptive Advisors may in the future engage in discussions with the [company] and third parties about potential strategic transactions; however, Perceptive Advisors is not currently aware of or participating in any such discussions."

13:36 EDT SharpLink Gaming announces 1-for-10 reverse stock split - SharpLink Gaming announced that pursuant to the shareholder approval at the extraordinary general meeting of shareholders held on January 20, the company's board of directors has determined to implement a reverse stock split of all of the company's share capital, including its ordinary shares, at a ratio of ten for one that will become effective on April 25. "SharpLink is undertaking the reverse stock split with the objective of meeting the minimum $1.00 per ordinary share bid requirement for maintaining the listing of its ordinary shares on The Nasdaq Capital Market," the company stated. On the effective date, SharpLink's 26,881,144 ordinary shares issued and outstanding will be reduced to approximately 2,688,114 ordinary shares issued and outstanding, and the total number of the company's authorized ordinary shares under its amended and restated articles and memorandum of association will be reduced from 92,900,000 ordinary shares to 9,290,000 ordinary shares, the company noted.

13:13 EDT FDA approves Biogen's Qalsody for ALS patients with SOD1 gene mutation - The Food and Drug Administration said it approved Qalsody to treat patients with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene. Qalsody is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. Reference Link

13:06 EDT First Republic trading halted, volatility trading pause

13:01 EDT Imax, CMX Cinemas expand partnership with three Imax locations in U.S. - CMX Cinemas and IMAX Corporation announced plans to expand their partnership with an agreement for three state-of-the-art IMAX with Laser systems in the United States. The deal will nearly double IMAX's footprint with CMX in Florida, delivering two brand new IMAX with Laser locations in the tourist hotspots of Daytona Beach and Palm Beach and upgrading one existing location in Miami. This new agreement expands on the relationship with CMX Cinemas that began in 2017. IMAX currently partners with CMX on five locations across the eastern U.S., including three existing locations in Florida. Nationally, CMX has a footprint of 30 locations spanning eight states across the country and has a strong regional presence in Florida with 17 locations across the state. "CMX Cinemas is thrilled to announce its extended partnership with IMAX, enabling us to provide a top-of-the-line cinematic experience to our guests through IMAX's premium technology," said Patrick Ryan, CEO of CMX Cinemas. "Our goal is to offer the most exceptional moviegoing experience possible, and we believe that, with IMAX's support, CMX Cinemas will remain a must-visit destination for film enthusiasts." The three new and upgraded locations for CMX include CMX Dolphin 19 in Miami, CMX Daytona 12 in Daytona Beach, and CMX Downtown at The Gardens 16 in Palm Beach. These screens will be equipped with IMAX with Laser.

12:50 EDT ZeniMax union begins first day of contract bargaining with Microsoft - ZeniMax Workers United of CWA, a union comprised of workers at Microsoft's ZeniMax subsidiary, said it has begun its first day of bargaining for its first ever contract between ZeniMax and Microsoft. The Fly notes that ZeniMax is the holding company behind popular video game franchises "Doom," "Fallout," "Elder Scrolls," and the upcoming "Starfield." Reference Link

12:20 EDT BCB Bancorp board approves continuation of stock repurchase program - BCB Bancorp announced that its Board of Directors has approved the Company to continue repurchasing shares of its issued and outstanding common stock through its active stock repurchase program, which was initially announced on October 17, 2022.

12:00 EDT Dingdong falls -11.2% - Dingdong is down -11.2%, or -44c to $3.49.

12:00 EDT First Republic falls -29.1% - First Republic is down -29.1%, or -$4.66 to $11.35.

12:00 EDT Unifi rises 18.8% - Unifi is up 18.8%, or $1.37 to $8.65.

11:42 EDT British American Tobacco reaches agreement with DOJ, OFAC - BAT announced that it has reached agreement with the U.S. Department of Justice, or DOJ, and U.S. Department of the Treasury's Office of Foreign Assets Control, or OFAC, to resolve previously disclosed investigations into suspicions of sanctions breaches. These concern business activities relating to the Democratic People's Republic of Korea, North Korea, between 2007 and 2017. British American Tobacco has entered into a deferred prosecution agreement with DOJ and a civil settlement agreement with OFAC, and an indirect BAT subsidiary in Singapore has entered into a plea agreement with DOJ. The total amount payable to the U.S. authorities is $635,241,338 plus interest. The DOJ resolutions acknowledged BAT's remediation efforts to date and cooperation. Under the agreement, BAT cannot make any comment on the documentation published by the investigating authorities, the contents therein, or on related factual matters. As announced in its Half-Year Report of 27 July 2022, BAT recognized a provision of $540 million, in line with the International Accounting Standards 37 requirements. Its Full Year 2023 Group guidance is unaffected by this announcement.

11:26 EDT GRI Bio Inc trading halted, volatility trading pause

11:09 EDT Paccar sees Q2 margins 18%-19% - Comments taken from Q1 earnings conference call.

10:44 EDT SCWorx signs New York hospital for data management, Workday assistance - SCWorx signed another new healthcare provider for its SaaS data management service offering and Workday implementation assistance. This new hospital customer, headquartered in New York, is a non-profit academic healthcare provider with over 400 beds under management. In addition to the company's data management service offering the hospital will utilize SCWorx expertise and application functionality to assist with the hospital's Workday implementation.

10:24 EDT Cleveland-Cliffs does not expect to operate Northshore in full anytime this year - Says higher level of steel production has led to the restart of some operations. Says Northshore has been idle since spring of last year. Says still does not expect to operate Northshore in full anytime this year. Says agnostic to whatever ways demand materializes. Says company is integral part of America's transition to EVs.

10:15 EDT JetBlue sees significant operational challenges this summer

10:08 EDT JetBlue sees more work to do to return margins to pre-pandemic levels, says CEO

10:01 EDT Curtiss-Wright awarded $28M Navy contract - Curtiss-Wright announced it has been awarded a five-year firm-fixed-price indefinite delivery, indefinite quantity contract by the Naval Air Systems Command, or NAVAIR. Under the multi-year program, with a maximum potential value of approximately $28M, Curtiss-Wright will provide E-28 Retrieve Drive Assemblies including spare parts supporting the replacement of the legacy sub-systems across U.S. Navy and Marine Corps bases.

10:00 EDT TrueBlue falls -12.2% - TrueBlue is down -12.2%, or -$2.12 to $15.16.

10:00 EDT Simpson Manufacturing rises 11.5% - Simpson Manufacturing is up 11.5%, or $12.97 to $125.95.

10:00 EDT Aaron's rises 26.2% - Aaron's is up 26.2%, or $2.68 to $12.90.

09:47 EDT UPS falls -7.2% - UPS is down -7.2%, or -$14.18 to $181.67.

09:47 EDT First Republic falls -26.2% - First Republic is down -26.2%, or -$4.19 to $11.81.

09:47 EDT Spotify rises 10.7% - Spotify is up 10.7%, or $14.04 to $145.49.

09:43 EDT Nevada reports March statewide gaming win down 3.18% to $1.31B - Nevada reports March Las Vegas Strip gaming win down 2.9% versus last year to $724.58M. Publicly traded companies in the gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn Entertainment (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

09:38 EDT Omnicom, Adobe partner for Content Supply Chain solution - Omnicom Group (OMC) is partnering with Adobe (ADBE) to reinvent the creation and delivery of creative content through an enterprise licensing deal of Adobe's new Content Supply Chain solution. Through the solution, Omnicom agencies across the globe will now have a unified view of every step of the content process, from planning and production to activation and optimization. The end-to-end solution will enable Omnicom's agencies to efficiently produce creative content that delivers the most effective customer experiences for the ultimate benefit of Omnicom's client roster of the world's top marketers and brands.

09:36 EDT Princess becomes official cruise vaction partner for Porsche Club of America - Princess Cruises is now the Official Cruise Vacation Partner for the Porsche Club of America. The move expands the cruise line's existing relationship with PCA which launched in 2022.

09:31 EDT OceanPal announces time charter contract for m/v Salt Lake City - The Company announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Pacbulk Shipping Pte. Ltd., for one of its Capesize dry bulk vessels, the m/v Salt Lake City. The gross charter rate is US$15,400 per day minus a 5% commission paid to third parties, for a period of minimum sixty days up to maximum July 29, 2023. The charter commenced yesterday. The m/v Salt Lake City was previously chartered to Richland Bulk Pte. Ltd., at a gross charter rate of US$5,100 per day, minus a 5% commission paid to third parties. The "Salt Lake City" is a 171,810 dwt Capesize dry bulk vessel built in 2005. The employment of "Salt Lake City" is anticipated to generate approximately US$924,000 of gross revenue for the minimum scheduled period of the time charter.

09:30 EDT OceanPal appoints Vasiliki Plousaki as CFO - OceanPal appointed Vasiliki Plousaki as the Company's new CFO, and appointed Margarita Veniou as the Company's Secretary in addition to her current position of Chief Corporate Development & Governance Officer, effective as of April 25, 2023. In their new roles, Ms. Plousaki and Ms. Veniou succeed Ioannis Zafirakis, who is resigning from his positions as the Company's Interim CFO, President and Secretary, offices he has held since November 2021. Mr. Zafirakis will continue to serve as a Class III director of the Company. Plousaki has served as the Chief Accounting Officer of the Company since June 2021, during which time she has been responsible for all financial reporting requirements. Veniou has served as Chief Corporate Development and Governance Officer of the Company since November 2021 and has been responsible for the implementation and supervision of general corporate matters, including the development of the Company's strategic plans.

09:28 EDT UPS says average daily volume down 5.4% y/y in Q1 - Says saw lower volume across all industry sectors. Says customers moving out of air and into ground freight. Says volume has stabilized in April. Expects volume to pick up in 2H23. Expects operating margin to improve in Q2. Says "making good progress" on Teamsters contract negotiations. Says "highly confident" in win-win agreement. Says continuing investments in projects that drive efficiency and growth. Says taking out semi-variable and fixed costs.

09:21 EDT Jamf showcases new functionality during special event - Jamf held a special Jamf Event to showcase a number of new offerings it has developed to help organizations deliver an enterprise-secure, consumer-simple environment that protects personal privacy. The forty-minute, live-streamed event is full of updates aimed at helping businesses, schools, and government entities succeed with Apple and also secure Android and Windows devices, regardless of their size or deployment requirements.

09:20 EDT Xponential Fitness in 'master franchise' pact in Japan for StretchLab - Xponential Fitness announced it has signed a Master Franchise Agreement in Japan for StretchLab. The agreement provides the Master Franchisee with the opportunity to license at least 40 StretchLab studios in Japan to potential franchisees over the next 10 years. As of December 31, Xponential had over 2,600 open studios worldwide, operating in 16 countries and four continents. The deal was signed with Sunpark of Osaka, a multi-brand operator and global franchisor of restaurants, entertainment concepts, and fitness centers with more than 100 locations in Japan, Singapore, Thailand and the United States. The StretchLab agreement marks Xponential's fifth brand to enter the Japanese market, following earlier agreements for Club Pilates, Rumble, CycleBar and AKT with Master Franchise Partner, Wellness X Asia. Wellness X Asia currently has 22 Club Pilates studios open in Japan, with the first studios of Rumble, AKT and CycleBar slated for later this year.

09:18 EDT Spotify jumps 8% after Q1 results and guidance - Shares of Spotify are up 8% or $10.50 at $141.95 in pre-market trading after the company's Q1 results and guidance.

09:18 EDT Grom Social's Curiosity Ink Media, WEP announce co-production partnership - Grom Social Enterprises announced that Curiosity Ink Media and WEP, LLC, will jointly co-develop and co-produce a feature film based on the iconic animated hit series, Denver, The Last Dinosaur.

09:17 EDT PowerBand Solutions currently not originating any new vehicle leases - PowerBand Solutions provides the following update on corporate activities. Following a detailed review of the business units operated within the Company's corporate structure, the management team provided shareholders with its updated corporate strategy which allocated all growth capital and resources to its used and new vehicle leasing platform, Drivrz Financial, as management believes it represents the highest near-to-medium-term return to shareholders. During the business unit review, management was notified by one of the financial institutions providing lease financing to DrivrzFinancial that certain vehicle leases originated in fiscal year 2021, and in the first quarter of 2022 fell within the repurchase criteria set forth in the Forward Flow Purchase and Security Agreement entered into between DrivrzFinancial and the Financial Institution. As noted in the Q3 September 30, 2022 Financial Statements and Management Discussion and Analysis, DrivrzFinancial repurchased vehicle leases for CAD $4,785,665. Since the beginning of Q1 2023, DrivrzFinancial and the Financial Institution have been in negotiations on additional lease contracts that the Financial Institution has identified fall within the repurchase criteria of the Forward Flow Purchase and Security Agreement. While the discussions have been ongoing the Financial Institution has not provided additional funding to DrivrzFinancial to originate vehicle leases. DrivrzFinancial's second lease funding provider is also currently withholding financing, although the lease portfolio of the second lease funding provider is performing within guidelines. The Company's management team is working to resolve matters with both financial institutions as soon as possible and be in a position to resume originating leases. In the first quarter of 2023, DrivrzFinancial was not able to obtain alternative sources of financing to fund new lease originations, and instead self-funded a total of five vehicle leases. To conserve working capital, the Company has decided to not self-fund any additional leases at this time. As a result, the Company is currently not originating any new vehicle leases while it works to resolve matters with its funding partners. DrivrzFinancial has implemented several measures to improve operations and to prevent future repurchase obligations. The executives and employees at DrivrzFinancial responsible for operations and underwriting when the repurchased leases were funded are no longer employed with the firm. The management team at PowerBand / DrivrzFinancial has hired several new experienced executives and employees, including a VP of Compliance and a new VP Servicing, to oversee the lease origination business. DrivrzFinancial has adopted a revised Credit Underwriting Policy & Procedures Manual and an updated DrivrzFinancial Funding Checklist. Additionally, DrivrzFinancial completed a comprehensive analysis of its entire lease portfolio and has identified dealers that it will no longer transact business with, thereby improving the credit profile of the portfolio and mitigating the risk of future lease repurchases. DrivrzFinancial has filed lawsuits against four dealers to recover damages and costs and has received judgements against three of these dealers. DrivrzFinancial has also issued additional demands to other dealers to repurchase leases that do not meet certain credit or legal criteria. PowerBand's management team continues to work diligently with the Financial Institution to resolve issues with the repurchasing of vehicle leases and to re-commence the origination of leases through the Forward Flow Purchase and Security Agreement. The Company is also seeking to secure additional funding lines for DrivrzFinancial.

09:13 EDT TG Venture Acquisition announces postponement of special meeting - TG Venture Acquisition announced that its special meeting of stockholders will be postponed from its original date of 10:00 a.m. Eastern Time on April 27, 2023 to 10:00 a.m. Eastern Time on May 4, 2023. The estimated redemption price per share is expected to remain approximately $10.37 at the time of the Special Meeting, as originally reported in TGVC's definitive proxy statement in connection with the Special Meeting filed with the U.S. Securities and Exchange Commission on April 10, 2023. The closing price of TGVC's common stock on April 24, 2023 was $10.37. TGVC also announced that if the proposals to amend TGVC's Amended and Restated Certificate of Incorporation and Investment Management Trust Agreement are approved at the Special Meeting, and the extension of TGVC's business combination period is implemented, TGVC's sponsor or its designees will deposit into TGVC's trust account established in connection with its initial public offering the lesser of $100,000 and $0.04 per share multiplied by the number of shares of TGVC Class A Common Stock originally sold as part of TGVC's initial public offering with the opportunity to redeem outstanding on the such applicable date, on each of May 5, 2023 and on the 5th day of each subsequent calendar month until November 5, 2023. TGVC has not asked its sponsor to reserve for, nor has TGVC independently verified whether its sponsor will have sufficient funds to satisfy, the Contribution.

09:10 EDT Tenable announces on-premises, hybrid deployment support for Tenable One - Tenable announced that its Tenable One Exposure Management Platform now supports on-premises and hybrid deployments via a new integration with Tenable Security Center 6.1. Tenable One streamlines exposure management for hybrid vulnerability management deployments and may help on-premises customers transition to the cloud more quickly. Tenable is now the only vendor to offer exposure management for both on-premises and hybrid deployment models.

09:09 EDT ZyVersa Therapeutics announces publication of article in journal on ASC specks - ZyVersa Therapeutics announces publication of an article in the peer-reviewed Journal of Neuroinflammation supporting the potential of ASC specks as a therapeutic target for Parkinson's disease. In the paper titled, "ASC specks exacerbate alpha-synuclein pathology via amplifying NLRP3 inflammasome activities," the authors reported data on the interplay between ASC speck formation, NLRP3 inflammasome activation, and pathological progression in a PD model. Following is a summary of key findings: There was a direct relationship between alpha-synuclein pathology and ASC expression; ASC specks enhanced NLRP3 inflammasome activation and reactive microgliosis; ASC specks accelerated dopaminergic neuron degeneration and dyskinesia; Knockdown of endogenous ASC markedly suppressed microglial inflammasome activation and neuronal alpha-synuclein aggregation under the challenge of PFFs. Stephen Glover, ZyVersa's Co-founder, Chairman, CEO and President, stated: "The research on the role of ASC Specks in propagation of alpha-synuclein pathology in Parkinson's disease published in the Journal of Neuroinflammation provides additional support for the therapeutic potential of ZyVersa's proprietary monoclonal antibody Inflammasome ASC Inhibitor IC 100, in neurological diseases. IC 100 preclinical studies demonstrate reduced inflammatory activity and/or improved outcomes in, age-related inflammation, Alzheimer's disease, multiple sclerosis, spinal cord injury, and two different models of brain injury."

09:07 EDT Nuvei integrates with Sabre to offer payments for the travel, hospitality - Nuvei Corporation (NVEI) announces that its market-leading payment platform is fully available on Sabre Corporation's (SABR) multiple reservation platforms for the travel and hospitality industries. Philip Fayer, Nuvei Chair and CEO, added: "By offering the most agile payments platform in the market, including an unmatched number of alternative payment methods through a single integration, we're enabling our customers to connect to their customers no matter how they want to pay. We continue to expand our use cases and penetrate markets with large TAMs, and further demonstrate how we accelerate our customers' growth."

09:06 EDT AMD introduces Ryzen Z1 series processors - AMD introduced the new Ryzen Z1 Series processors, the ultimate high-performance processor for handheld PC gaming consoles1. The Ryzen Z1 Series features two high performance processors, the Ryzen Z1 and Ryzen Z1 Extreme, both offering industry-leading gaming experiences, uncompromising battery life, and featuring AMD RDNA 3 architecture-based graphics. AMD is partnering with Asus to launch the first Ryzen Z1 Series device with the Asus ROG Ally, a premium handheld PC console, featuring up to a Ryzen Z1 Extreme processor.

09:05 EDT Formula One, Custom Events from WSJ to host F1 Accelerate Summit - Formula 1 is partnering with Custom Events from WSJ, a commercial unit of Dow Jones, publisher of The Wall Street Journal, to host the F1 Accelerate Summit on Thursday, May 4, 2023.

09:03 EDT IBM, Noname Security collaborate to deliver advanced API security offerings - Noname Security announced its collaboration with IBM to potentially help further protect customers from vulnerabilities, misconfigurations, and design flaws. With the new Noname Advanced API Security for IBM, customers will be able to leverage Noname Security's API security solution, combined with the standing enterprise security capabilities of IBM DataPower, to provide an additional layer of protection for IBM API Connect. By leveraging Noname Security technology with IBM API Connect and IBM DataPower, customers will be able to experience advanced API management capabilities and automatically discover APIs, providing insights into API behavior, and support compliance requirements. "Our enterprise customers require the best security when using APIs across their organization," said Eileen Lowry, Vice President, IBM Automation - Integration at IBM. "By collaborating with Noname Security, we intend to add an additional layer of security to our solutions and will continue to help protect IBM API Connect customers from potential cyber threats. We intend to bring an innovative provider of intelligent API security solutions to IBM API Connect and IBM DataPower."

09:02 EDT Jack in the Box's Del Taco expands footprint in greater Atlanta market - Del Taco announced the opening of its newest location in the Atlanta Metro area at 6705 Jonesboro Road, Morrow, GA 30260. The new restaurant opening is part of the brand's multi-unit deal with franchisee veteran Mac Kamara of MK Energy and will serve as the 21st Del Taco location in the Georgia market. "It's a great source of pride to unveil one of Del Taco's first Fresh Flex restaurants here in Morrow. The residents of the greater Atlanta area know Del Taco well and we know they will appreciate the new design that enhances the guest experience by doubling down on efficiency and promoting ease of to-go meals," said Mac Kamara. Kamara is a seasoned Del Taco franchisee partner with nearly 20 years of experience in the food industry and has served as owner and operator of BP and Subway locations.

08:58 EDT Verizon anticipates $75M in incremental quarterly revenue moving forward - Says now seeing return of voluntary churn rates to pre pandemic levels. Says encouraged by improved churn level at end of Q1. Says enters Q2 with more momentum than a year ago. Says expects pressure on pre-paid net adds to increase in Q2. Says anticipates $75M in incremental quarterly revenue moving forward. Sees FY23 capital expenditures $18.25B-$19.25B. Comments and guidance taken from Q1 earnings conference call.

08:54 EDT Netlist wins $303M award in patent infringement trial against Samsung - Yesterday, Netlist (NLST) "announced that it won a $303 million damages award against Samsung Electronics (SSNLF) Samsung Semiconductor, Inc., and Samsung Electronics America in the United States District Court for the Eastern District of Texas. The award resulted from a jury trial that lasted six days, and involved five Netlist patents: U.S. Patent Nos. 10,949,339, 11,016,918, 11,232,054, 8,787,060, and 9,318,160. The products found to infringe these patents were all Samsung DDR4 LRDIMM, DDR5 UDIMM, SODIMM, and RDIMM, and high bandwidth memory 2, 2E and 3 components." C.K. Hong, Netlist's CEO,, said, "We are pleased with the outcome of this case. The jury verdict left no doubt that Samsung not only willfully infringed Netlist patents, but currently uses Netlist technology without a license on strategic products which collectively represent the future of Samsung's memory business. The brazen free-ride and efficient infringement of intellectual property belonging to small innovators by industry giants remain a serious issue for our innovation ecosystem. We hope this case serves as a reminder of this problem to policymakers as well as a wakeup call to those in the memory industry that are using our IP without permission."

08:49 EDT General Motors CFO says still planning for 15M unit U.S. SAAR in 2023 - GM CFO Paul Jacobson said during the company's Q1 call: "We are still planning to a 15 million unit SAAR and targeting to end 2023 with 50 to 60 days of total dealer inventory. Although seasonality production schedules and timing of fleet deliveries may take us out of this range from time to time."

08:49 EDT GRI Bio appoints Leanne Kelly as Chief Financial Officer - GRI Bio (GRI) announced the appointment of Leanne Kelly as its Chief Financial Officer. Prior to her appointment at GRI Bio, Kelly served as the Chief Financial Officer of Vallon Pharmaceuticals (VLON), which recently announced the completion of its merger with GRI Bio.

08:48 EDT 1847 Holdings' ICU Eyewear enters LOI for $15M revolving credit line facility - 1847 Holdings announced that its subsidiary, ICU Eyewear Holdings, has entered into a letter of intent for a $15M revolving credit line facility with an asset-based lender to fund ICU's growth. The establishment of the credit facility is subject to the completion of due diligence by the lender and the entry into a definitive credit agreement and related documents and the satisfaction of all conditions included in such documents.

08:47 EDT McDonald's sees potential for recessionary environment

08:47 EDT BK Technologies receives $970,000 order for BKR 5000 radios - BK Technologies has received a purchase order valued at $970,000 from the Oregon/Washington Bureau of Land Management. The order includes the Company's BKR 5000 radio as the agency conducts a lifecycle replacement program for its communications technology.

08:46 EDT Ageagle awarded five-year MAS contract by U.S. GSA - AgEagle Aerial Systems has been awarded a Multiple Award Schedule Contract by the General Services Administration, which is the centralized procurement arm of the federal government.

08:45 EDT UPS says saw a shift in consumer spending in Q1 - Says U.S. discretionary sales lagging grocery and consumable sales. Says disposable income shifting from goods to services. Says increased penetration in most attractive parts of the market. Says operating profit/margin in line with base plan in Q1. Says negotiations on new Teamsters contract are underway; confident in an agreement by end of July. Says there has been a deceleration in U.S. retail sales growth, and certain non-U.S. markets remain challenged. Comments taken from Q1 earnings conference call.

08:43 EDT General Motors sees 600,000 EV truck capacity with Orion reopens - General Motors CEO Mary Barra said on the company's Q1 earnings call: "As Paul and I have shared, we plan to produce 400,000 EVs over the course of '22, '23 and the first half of 2024, including 50,000 EVs in North America in the first half of this year and double that in the second half... All of this is enabled by rising production at Ultium cells in Ohio, which we expect to reach full capacity at the end of the year. Everything we learned in Ohio will be applied to our next-use LTM cell plants, including in Tennessee, where we will begin hiring and training production workers in a matter of weeks. Work also continues to transform our assembly plant in Orion Township, Michigan to build the GMC Sierra EV and the Chevrolet Silverado EV. We have progressed so far, that it's now time to plan to end the Chevrolet Bolt EV and EUV production, which will happen at the very end of the year. When Orion EV assembly reopens in 2024 and reaches full production, employment will nearly triple, and we'll have a company-wide capacity to build 600,000 electric trucks annually. We'll need this capacity because our trucks more than measure up to our customers' expectation, and we'll demonstrate that work and EV range are not mutually exclusive terms for Chevrolet and GMC trucks."

08:43 EDT McDonald's CFO: Rising costs pressuring consumer spending across markets

08:40 EDT Maxeon Solar announces partnership with Nanyang Technological University - Maxeon Solar Technologies has launched a partnership with Nanyang Technological University, Singapore, or NTU Singapore, through its Energy Research Institute at NTU, or ERI@n, to research ways to improve solar recycling. Recycling is a key challenge for the solar industry as older panels reach the end of their useful lives. This partnership is part of Maxeon's effort to power a circular economy, an ongoing project that the company has synthesized into a single comprehensive circular economy policy document published today too: 'Powering a Circular Economy: Sustainable Manufacturing and Recycling'. NTU ERI@N is a leading energy-focused research institute in Asia with comprehensive research facilities and deep expertise in the area of solar recycling. Through this partnership, NTU ERI@N and Maxeon Solar Technologies will collaborate to investigate green chemistries, explore opportunities for upcycling components, and identify ways to maximise material recovery. NTU ERI@N will also perform a comprehensive lifecycle assessment of Maxeon's high-efficiency Interdigitated Back Contact panels at the end of their useful life.

08:39 EDT Cellebrite appoints Mark Fitzsimons as MD, APAC business - Cellebrite DI announced that Mark Fitzsimons has been named Managing Director for the company's Asia-Pacific business, effective April 17, 2023.Based in Singapore, Fitzsimons will lead Cellebrite's business activity in the Asia Pacific region. Fitzsimons will report to Arthur Veinstein, President, International at Cellebrite, and be a key leader in the expansion and accelerating Cellebrite's growth in the APAC region. Fitzsimons previously led sales and strategic initiatives for a variety of organizations, including Everise, Gredit Finance, and Software AG.

08:37 EDT PureCycle Ironton PP purification plant reaches mechanical completion - PureCycle Technologies (PCT) announced it has reached mechanical completion of its first polypropylene, or PP, purification plant in Ironton, OH, and submitted documentation to Leidos Engineering, the site's independent construction monitor, for formal certification of completion. PureCycle prepared the final closure documentation consistent with the requirements set forth by Leidos and believes the information to be complete and sufficient. The Leidos certification is required to achieve key milestones in connection with PureCycle's Ironton financings. Contemporaneous with, and independent of, the Leidos (LDOS) certification process, the Ironton Facility will now begin operational pre-startup, safety review processes, and the march toward initial pellet production, which is currently anticipated to commence in the Q2. The Ironton Facility, once fully operational, is expected to produce 107 million pounds of Ultra-Pure Recycled resin annually, making high-quality recycled PP plastic more accessible at scale. PureCycle's first purification plant will provide the Ironton community with an influx of new jobs.

08:37 EDT Iteris awarded contract to support MnDOT for MOT for I-494 project - Iteris announced it has been chosen by the Minnesota Department of Transportation MnDOT to provide performance-based maintenance of traffic MOT in support of the I-494 Improvement Project in the Minneapolis area. The $377M I-494 construction design-build project will be led by C.S. McCrossan Construction, Inc. and aims to improve the portion of I-494 that travels from East Bush Lake Road to 12th Avenue. New E-Z Pass HOV lanes will be installed in both directions, and multiple interchanges and accesses will be reconstructed or reconfigured. It will also include the construction of 12 new bridges, more than 30 retaining walls, new noise abatement walls and new drainage infrastructure. Iteris will be responsible for monitoring and managing the local arterial network throughout this project to ensure the major construction does not increase delays beyond what MnDOT and local agencies have mandated. The local arterial network will span through the cities of Bloomington, Richfield, Eden Prairie and Edina...Iteris will be responsible for monitoring and managing the local arterial network throughout this project to ensure the major construction does not increase delays beyond what MnDOT and local agencies have mandated. The local arterial network will span through the cities of Bloomington, Richfield, Eden Prairie and Edina.

08:37 EDT PureCycle Ironton PP purification plant reaches mechanical completion - PureCycle Technologies announced it has reached mechanical completion of its first polypropylene, or PP, purification plant in Ironton, OH, and submitted documentation to Leidos Engineering, the site's independent construction monitor, for formal certification of completion. PureCycle prepared the final closure documentation consistent with the requirements set forth by Leidos and believes the information to be complete and sufficient. The Leidos certification is required to achieve key milestones in connection with PureCycle's Ironton financings. Contemporaneous with, and independent of, the Leidos certification process, the Ironton Facility will now begin operational pre-startup, safety review processes, and the march toward initial pellet production, which is currently anticipated to commence in the Q2. The Ironton Facility, once fully operational, is expected to produce 107 million pounds of Ultra-Pure Recycled resin annually, making high-quality recycled PP plastic more accessible at scale. PureCycle's first purification plant will provide the Ironton community with an influx of new jobs.

08:36 EDT Artelo Biosciences initiates Phase 2a portion of CAReS trial of ART27.13 - Artelo Biosciences announced it has initiated the Phase 2a portion of its Cancer Appetite Recovery Study evaluating ART27.13 for the treatment of cancer-related anorexia and weight loss. The Phase 2a portion of the CAReS study is a double-blind, placebo-controlled design enrolling 40 patients randomly allocated in a 3:1 ratio to receive ART27.12 or placebo once daily for up to 12 weeks. The study is planned to be conducted at approximately 18 clinical sites in five countries.

08:34 EDT Cryoport signs new agreement with Boston IVF - Cryoport announced that it has signed a new three-year agreement with Boston IVF, an experienced fertility treatment provider. Utilizing Cryoport's end-to-end supply chain solutions, Boston IVF will now have the ability to integrate its regional and satellite labs across Massachusetts, New Hampshire, Maine, Rhode Island, New York and Indiana, along with its partner sites in Delaware, Ohio, Idaho, Utah and North Carolina. Cryoport's platform will improve the overall efficiency of Boston IVF's reproductive material shipments and ensure significant risk mitigation for patients and families entrusting Boston IVF with their care.

08:33 EDT McDonald's operating from a position of strength, says CEO - Comments taken from Q1 earnings conference call.

08:33 EDT MSA Safety awarded $15M contract by Los Angeles City Fire Department - MSA Safety announced that the Los Angeles City Fire Department has selected MSA Safety's respiratory protective equipment in a $15M contract award. This represents the first of what the company expects to be a two-phase order. MSA Safety anticipates receiving a second contract from LA City in the Q3 totaling approximately $9M. With this contract, MSA continues to strengthen its breathing apparatus market presence in the Southern California region. In July of last year, MSA Safety announced a similar-size breathing apparatus contact with the Los Angeles County Fire Department. Delivery of the new SCBA units is expected to begin immediately and be completed by the end of Q4.

08:32 EDT Fresh Vine appoints Roger Cockroft as CEO - Fresh Vine Wine announced that its Board of Director has appointed Roger Cockroft as its new CEO. Roger Cockroft is currently Executive Partner at Salt Creek Capital, a San Francisco Bay Area private equity firm acquiring profitable, lower middle market businesses across the U.S.

08:29 EDT Twin Vee PowerCats' factory expansion receives final site plan approval - Twin Vee PowerCats is moving forward with its planned factory expansion after the City Commission of the City of Fort Pierce voted to approve the plan last week. Twin Vee headquarters, located on a 7.27-acre parcel in Fort Pierce, Florida, currently consists of two detached buildings for boat production and storage. When construction is completed, an all-new 23,456-square-foot one-story building and a 4,389-square-foot covered awning will connect the two existing structures, creating a 95,000-square-foot space for the manufacturing facility.

08:23 EDT Enanta sells 54.5% of future royalty payments from Mavyret/Maviret for $200M - Enanta (ENTA) announced the sale to Omers, one of Canada's largest defined benefit pension plans, of 54.5% of Enanta's future royalty payments from AbbVie (ABBV) on worldwide sales of Mavyret/Maviret. The purchase price paid to Enanta was $200M. OMERS right to receive royalty payments is based on net sales of the product beginning in July through June 2032, with total payments capped at 1.42 times the purchase price. Enanta retains 45.5% of all royalties until the cap is hit, at which point 100% of all further royalties revert to Enanta.

08:19 EDT PharmAla Biotech to supply Incannex with LaNEO MDMA, psilocybin - PharmAla Biotech received a signed purchase order for GMP LaNeo MDMA and Psilocybin by Incannex.

08:18 EDT Vaccinex completes enrollment in Phase 1b/2 SIGNAL-AD study of Pepinemab - Vaccinex announced that it has completed enrollment goal in the SIGNAL-AD clinical trial for people with mild dementia due to Alzheimer's Disease. Topline data from the study are expected in mid-2024, after the last enrolled patients will have received 12 months of treatment. "Completing enrollment in the SIGNAL-AD study is a major accomplishment for Vaccinex and the first of several important milestones anticipated in the second quarter of 2023," said Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex. "While the treatment phase of the SIGNAL-AD study is ongoing, we are expecting FDA response to proposed plans for the design of a Phase 3 study in HD. Study data have been submitted to the FDA and a response is anticipated on or before May 16, 2023. Multiple prior clinical studies in AD have shown that, as in HD, a decline in brain metabolic activity correlates with disease progression. Pepinemab is the only clinical intervention to date that has been shown to reduce or prevent decline in brain metabolic activity while also appearing to slow or prevent cognitive decline. Based on the clinical data and favorable profile from the SIGNAL study in HD, we are hopeful that treatment with pepinemab can open the door to a safe and effective, disease modifying treatment option for patients with Alzheimer's Disease. Disease-related stress, such as is induced by accumulation of toxic aggregates of beta-amyloid in AD and mutant huntingtin protein in HD, activate inflammatory cells in brain that inhibit normal healthy functions of neurons and aggravate neurodegeneration. We believe that blocking neuroinflammatory signals with pepinemab represents a novel approach to treating NDD with the potential to complement independent amyloid-lowering strategies," continued Dr. Zauderer. "We are very appreciative of patients and their families for their dedication to advancing research by participating in this and similar important studies. We look forward to share the results of this study with the NDD/AD communities in mid-2024 and will continue to work with our advisors and regulators to chart a course for potential next steps for pepinemab in treatment of neurodegenerative disease."

08:15 EDT Wejo announces it has joined the Rekor Partner Network - Wejo Group (WEJO) and Rekor Systems (REKR) announced that Wejo has joined the Rekor Partner Network, RPN. The RPN is a global ecosystem of technology, data, and solution providers working together to provide the most comprehensive view of the world's roadway data and intelligence available, streamlining innovation and solving transportation and mobility challenges. Rekor utilizes Wejo and other connected vehicle data to identify road incidents that may not have been reported, resulting in a 23% increase in detection rates. This technology is particularly effective in rural areas, providing superior coverage compared to traditional methods of incident detection. By leveraging CVD, Traffic Management Centers in Departments of Transportation can now identify and respond to incidents up to 15 minutes faster, resulting in faster incident response and recovery and reducing the occurrence of secondary incidents and congestion. "We are excited to partner with Rekor and make Wejo's CVD accessible to Rekor's customers," said Richard Barlow, Found and CEO of Wejo. "The wealth of data available we are able to provide includes trillions of data points from over 20 million vehicles enabling agencies to better understand trends in their roadway network and optimize their planning and response. By working together, Rekor and Wejo aim to make our roads safer, smarter, and more efficient, ultimately improving the lives of all road users."

08:13 EDT Purple Biotech debuts Scientific Advisory Board - Purple Biotech announced the inauguration of its Scientific Advisory Board, SAB. Purple Biotech anticipates conducting regular SAB meetings to advise and assist management with significant scientific judgement regarding its clinical trials as well as to perform external scientific review of pre-clinical and R&D activities. The members of the SAB are: Eyal Gottlieb, PhD, is a Professor at the Department of Cancer Biology and Vice President for Research at The University of Texas M.D. Anderson Cancer Center. Steven Maron, MD, MSc, is a medical oncologist at Memorial Sloan Kettering Cancer Center who specializes in treating gastrointestinal malignancies with a focus on esophageal and stomach cancers. Sunil Sharma, MD, MBA, is Physician in Chief, Deputy Director of Clinical Sciences and Professor and Division Director of Applied Cancer Research and Drug Discovery at Translational Genomics.

08:13 EDT UPS cites 'challenging macro conditions' for revised FY23 guidance - In January, UPS provided a range for its 2023 financial targets based on the macroeconomic forecast at that time. Over the first quarter of 2023, the global volume environment deteriorated due to challenging macro conditions and changes in consumer behavior. As a result, UPS expects full-year revenue and adjusted operating margin to be at the low end of its previously guided range.

08:12 EDT Erasca announces publication of clinical data on naporafenib - Erasca announced the publication of results in the Journal of Clinical Oncology from the expansion arm of a Phase 1b open label study evaluating pan-RAF inhibitor naporafenib plus MEK inhibitor trametinib in patients with NRAS-mutant, NRASm, melanoma. Publication Highlights: Initial Evidence for the Efficacy of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase 1b, Open-Label Study. Dual blockade of the RAS/MAPK pathway has proven to be highly efficacious in patients with BRAF-mutant melanoma. However, similar dual blockade has not been approved in patients with NRASm melanoma. This Novartis-sponsored Phase 1b study evaluated the safety and preliminary efficacy of naporafenib plus trametinib at two recommended doses for expansion in patients with NRAS-mutant melanoma. Naporafenib plus trametinib demonstrated promising preliminary antitumor activity in heavily pretreated patients; The safety profile of the combination was manageable with low discontinuation rates due to adverse events; Naporafenib 200 mg BID + trametinib 1 mg QD vs. naporafenib 400 mg BID + trametinib 0.5 mg QD: Confirmed objective response rate: 46.7% vs. 13.3%, Median duration of response: 3.75 months vs. 3.75 months, Median progression-free survival: 5.5 months vs. 4.2 months.

08:11 EDT Blue Water management to attend AUA Annual Meeting 2023 - Blue Water Biotech announced that Blue Water management will attend the American Urological Association, AUA, Annual Meeting 2023 in Chicago, IL from April 28th to May 1st, 2023, to promote its asset ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia, BPH. Blue Water's Chief Executive Officer, Joseph Hernandez, and Senior Vice President of Marketing and Business Development, Frank Jaeger, will be in attendance to discuss launch strategy for ENTADFI scheduled for later this year, as well as the benefits of ENTADFI versus traditional BPH therapies. "This conference brings together the top urology leaders from around the country, and we are thrilled to attend to promote ENTADFI," said Hernandez. "We believe this product has the potential to transform the BPH landscape and enhance the lives of millions of men that suffer from BPH and associated erectile dysfunction. We encourage all in attendance to visit our booth to connect and learn about ENTADFI(R), as we prepare for launch later this year."

08:09 EDT TG Therapeutics to present data from ULTIMATE I & II Phase 3 trials of BRIUMVI - TG Therapeutics announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis, RMS, at the American Academy of Neurology, AAN, annual meeting. Michael Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, "We are pleased to present additional analyses from the ULTIMATE I & II Phase 3 trials and further in-vitro characterization of BRIUMVI at the AAN conference this week. We look forward to continuing to share additional exploratory analyses throughout the year."

08:09 EDT Academy Sports to open first location in Peoria, Illinois in summer 2023 - Academy Sports will open its first location in Peoria, IL in the summer of 2023. This is Academy's second location in Illinois which is set to open in Grand Prairie Plaza and will be over 60,000 square feet. Academy plans to continue its expansion efforts with the goal of opening 13 - 15 stores this year, and a total of 120 to 140 new stores by the end of 2027.

08:09 EDT iCAD announces 'Profound Insights, ProFound Impact' webinar event - iCAD announced its "ProFound Insights, ProFound Impact" webinar series will feature Kathy Schilling, MD, Medical Director, Christine E. Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital. The live event, titled "Elevating Accuracy Across the Board at Boca Raton Regional Hospital" will take place on Wednesday, May 24 at 10 am ET. The event will be moderated by iCAD's President and CEO, Dana Brown. To register, visit this link. During the event, Dr. Schilling will discuss the research she recently presented at the European Congress of Radiology meeting demonstrating how ProFound AI helped nine dedicated breast radiologists at the facility find 23% more cancers, without increasing the rate of recalls. She will also present a live clinical case review showcasing how ProFound AI can enhance cancer detection in a clinical setting.

08:08 EDT Intuitive Surgical director sells $2.42M in common stock - In a regulatory filing last night, Intuitive Surgical disclosed that its director Mark Rubash sold 8.1K shares of common stock on April 21st in a total transaction size of $2.42M.

08:07 EDT Cue Biopharma appoints Pamela Garzone to board of directors - Cue Biopharma announced the appointment of Pamela Garzone, Ph.D., to its board of directors. She is currently the chief development officer of Anixa Biosciences, where she oversees a portfolio in oncology.

08:06 EDT NV5 Global awarded $16M in California utility gas pipeline design, support - NV5 Global announced that it has been awarded $16M in utility gas pipeline design and support services contracts by two prominent California gas utilities. NV5 will provide engineering design, plan review, permitting support, and municipal consulting services for asset integrity management and pipeline improvements to support the safe and reliable delivery of natural gas as follows. A large California gas utility selected NV5 for $9M in contracts to provide gas transmission design and pipeline support services for system integrity management and capital replacement projects. Under the scope of these agreements, NV5 will deliver engineering design, project management, construction management, traffic control, and permitting services to support the utility's safety enhancement programs. NV5 was also awarded $7M in design, municipal consulting, and emergency services contracts by a major California gas and electrical utility. NV5 will review proposed municipal and state government infrastructure designs to identify potential conflicts with utility assets and support negotiations to mitigate risks to existing and proposed infrastructure. NV5 will also provide support services for emergency gas repairs to comply with municipal excavation permit requirements.

08:05 EDT Science 37 appoints Erica Prowisor as SVP, patient and provider networks - Science 37 Holdings announced Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies. Erica has been forging new ground as a leader in patient recruitment for nearly 20 years, most notably with IQVIA where she was Global Head of Recruitment and Retention for more than three years and led the company's direct-to-patient recruitment and retention efforts.

08:05 EDT Lyra Therapeutics announces restart of Phase 3 ENLIGHTEN II trial of LYR-210 - Lyra Therapeutics announced that it has resumed screening and enrollment in ENLIGHTEN II, its second pivotal Phase 3 clinical trial of LYR-210 in patients with CRS. The ENLIGHTEN program consists of two pivotal Phase 3 clinical trials, ENLIGHTEN I and ENLIGHTEN II, to evaluate the efficacy and safety of LYR-210 for the treatment of CRS. Enrollment in the ENLIGHTEN I clinical trial remains on track, with pivotal data anticipated in 1H 2024. Lyra announced in November 2022 that it temporarily paused enrollment in ENLIGHTEN II due to a transition to in-house manufacturing to ensure consistent clinical supply of LYR-210. The Company expects to complete enrollment in the ENLIGHTEN II trial in the second half of 2024. Lyra is manufacturing LYR-210 in house for both ENLIGHTEN trials. "Our in-house manufacturing team was able to expedite the increased production of LYR-210 to allow us to resume enrollment in ENLIGHTEN II ahead of our original expectation of third quarter of 2023," said Maria Palasis, Ph.D., President and CEO of Lyra. "We believe that Lyra's internal manufacturing capabilities and quality systems will continue to strengthen our ability to expedite our promising candidates toward approval and commercialization, while reducing regulatory risk and risks associated with technology transfer to third parties."

08:04 EDT Accenture, Palo Alto Networks collaborate to deliver SASE solutions - Accenture (ACN) and Palo Alto Networks (PANW) are collaborating to deliver joint secure access service edge, or SASE, solutions powered by Palo Alto Networks AI-powered Prisma SASE, enabling organizations to improve their cyber resilience and accelerate business transformation efforts. The transition to remote work and multi-cloud environments means that users, applications and data are distributed across multiple networks, resulting in increased risk and complexity. SASE solutions, which are cloud-based, provide highly granular authentication and authorization, giving organizations a better understanding of the users in their environments and enabling them to control what applications

07:58 EDT Nikola sells first electric vehicles to Alberta Motor Transport Association - Nikola announces the expansion of its presence in Alberta, Canada, with the sale of a Nikola Tre battery-electric vehicle, or BEV, and a Nikola Tre hydrogen fuel cell electric vehicle to the Alberta Motor Transport Association, or AMTA. AMTA is combining this purchase with refueling support, via access to Nikola's innovative hydrogen mobile fueler. AMTA will incorporate the new heavy-duty vehicles into its Hydrogen Commercial Vehicle Demonstrations Project. This first-of-its-kind project in Canada officially launched on February 10, and offers Alberta carriers the opportunity to use and test Class 8 vehicles that operate with hydrogen fuel within their unique operations. These trials will look at the performance of hydrogen-fueled vehicles on Alberta roads, payloads, and weather conditions, while addressing challenges around fuel cell reliability, infrastructure, and vehicle cost and maintenance. The Nikola Tre BEV has a range of up to 530 km, one of the longest of the battery-electric zero-emission Class 8 tractors.

07:57 EDT Spotify reports Q1 total MAUs 515M vs. 422M last year

07:49 EDT General Electric still expects offshore to remain near-term challenge

07:48 EDT General Electric sees 70%-75% of Power's total profit in 2H

07:47 EDT General Electric sees inflection for Renewables in profitability in FY24

07:45 EDT Diageo announces voluntary delisting from Euronext Paris - Diageo announces that the delisting of its shares from Euronext Paris has been approved by the board of directors of Euronext Paris. It is currently anticipated that the Paris Delisting will take effect on 26 May 2023. The decision by Diageo to delist was taken following a review of the trading volumes, costs and administrative requirements related to its listing on Euronext Paris. The delisting from Euronext Paris will not have any impact on Diageo's day-to-day operations in France. Diageo's listings on the London Stock Exchange and the New York Stock Exchange will not be impacted by the delisting from Euronext Paris. Following the announcement made on 13 April 2023, Diageo has also submitted an application for the delisting of its ordinary shares from Euronext Dublin. Euronext Dublin has now confirmed that it requires no further information from Diageo to effect the Dublin Delisting. It is currently anticipated that the Dublin Delisting will take effect on or around 30 May 2023, approximately one business day after the Paris Delisting has taken effect. Diageo will publish a further announcement when the Dublin Delisting has taken effect. A voluntary sales facility procedure will be put in place in accordance with Euronext Paris' rules to allow shareholders to sell their Diageo shares listed on Euronext Paris and held in the Euroclear France clearing system. Diageo has appointed Uptevia to act as centralising agent in connection with the voluntary sales facility.

07:43 EDT Tracon announces $23M arbitration award in dispute with I-Mab - TRACON Pharmaceuticals (TCON) announced that the tribunal in the arbitration against I-Mab (IMAB) conducted under the Rules of Arbitration of the International Chamber of Commerce rendered an award to TRACON in the aggregate amount of approximately $23M. In November 2018, TRACON entered into two separate strategic collaboration and clinical trial agreements with I-Mab for the development of multiple immuno-oncology programs, including I-Mab's proprietary CD73 antibody TJ004309 as well as up to five proprietary bispecific antibodies under development by I-Mab. I-Mab commenced arbitration in June 2020, after TRACON invoked contractual dispute resolution provisions asserting that I-Mab had breached its contractual obligations. I-Mab initiated the arbitration seeking a declaration that they were not in breach of either agreement, and TRACON filed counterclaims soon thereafter. Among other findings, the ICC tribunal deemed the TJ004309 trial complete as of January 2022, which entitled TRACON to $9M plus interest, and awarded legal fees and costs to TRACON. The award is made pursuant to a binding arbitration, and both agreements are now terminated. "We are pleased to receive an award from the ICC tribunal, that we believe will extend our runway into 2024 past the expected interim efficacy results from ENVASARC," said Charles Theuer, CEO."We remain focused on the pivotal ENVASARC Phase 2 trial and expect to complete enrollment this year."

07:41 EDT Nextech3D.ai receives CSE conditional listing approval for Toggle3D.ai - Nextech3D.AI has received conditional listing approval from the Canadian Securities Exchange for Toggle3D.ai. The company said, "Toggle3D is an AR enhanced standalone web application which enables product designers, 3D artists, marketing professionals and eCommerce site owners to create, customize and publish high-quality 3D models and experiences without any technical or 3D design knowledge required." Toggle3D.ai Listing Updates: The Company has received conditional listing approval for Toggle3D.ai from the CSE. The approved new CSE trading symbol: TGGL. Trade date is expected to be in the first half of June, 2023 on the CSE. The Company has begun working on getting dual-listed in the United States on the OTC, and Internationally on the Frankfurt Stock Exchange. On April 27th, 2023 the Toggle3D.ai prospectus mailing to 30,000 Nextech3D.ai shareholders is expected to occur using notice-and-access procedures to deliver the 2023 Meeting materials to beneficial Shareholders. Annual General and Special Meeting is scheduled to take place virtually on June 5th 2023 at 10:00 a.m. After the AGSM meeting, the final hearing to approve the plan of arrangement is scheduled for June 9th with a listing date of Toggle3D.ai shortly after. Initially announced in February 2023, the Company is closing in on finalizing the spin-off. The spin-off will result in Toggle3D.ai as a stand alone public company, with Nextech3D.ai retaining an aggregate of 13,000,000 common shares and Nextech shareholders of record receiving a total of 4,000,000 newly issued dividend shares in Toggle3D.ai on a pro-rata basis.

07:38 EDT NextEra Energy sees 6%-8% annual growth rate through 2026 - The company expects 6%-8% annual growth rate through 2026, off the 2024 adjusted EPS expectations range. From 2021 to 2026 expects compound annual growth in operating cash flow to be at or above our adjusted EPS growth rate. Continue to expect ~10% annual dividend per share growth through at least 2024.

07:36 EDT Reunion Neuroscience receives notice of non-compliance from Nasdaq - Reunion Neuroscience received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company's common shares for the 30 consecutive business day period between March 7, 2023, through April 18, 2023, the Company did not meet the minimum bid price of U.S. $1.00 per common share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company's common shares on the Nasdaq Global Select Market. The letter also indicated that, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company will be provided with a compliance period of 180 calendar days, or until October 16, 2023 , to regain compliance. In order to regain compliance with NASDAQ's minimum bid price requirement, the Company's common shares must maintain a minimum closing bid price of at least U.S. $1.00 for a minimum of ten consecutive business days during the Compliance Period. In the event the Company does not regain compliance with Nasdaq Listing Rule 5450(a)(1) by the end of the Compliance Period, the Company may be eligible for an additional 180 calendar days to regain compliance in accordance with Nasdaq Listing Rule 5810(c)(3)(A)(ii). However, if it appears to NASDAQ that the Company will be unable to cure the deficiency, or if the Company is not otherwise eligible for the additional cure period, the Company may face delisting. The letter has no immediate impact on the Company's business operations or listing of the Company's common shares, which will continue to be listed and traded on the Nasdaq Global Select Market, subject to the Company's compliance with the other listing requirements of the Nasdaq Global Select Market.

07:35 EDT Marimed announces opening of Panacea Wellness Dispensary in Massachusetts - MariMed announced it opened an adult-use only Panacea Wellness Dispensary in Beverly, Massachusetts, marking the Company's third operational dispensary in the state and the tenth dispensary that MariMed owns or manages across four states. The dispensary is located at 13 Enon Street in Beverly, a densely populated city located north of Boston. The Company plans to celebrate with a Grand Opening on April 27th, which will continue through April 29th.

07:32 EDT Arbutus Biopharma announces FDA clinical hold on IND for AB-101 - Arbutus Biopharma announced that the Company was notified via verbal communication from the U.S. Food and Drug Administration that the AB-101 Investigational New Drug application has been placed on clinical hold. AB-101 is a novel, oral PD-L1 inhibitor designed to reawaken and boost the immune system of patients with chronic hepatitis B virus. The FDA indicated they will provide an official Clinical Hold letter to Arbutus within 30 days. Based on this communication, the Company no longer intends to report initial data from the single-ascending dose portion of the Phase 1 clinical trial in the second half of 2023.

07:22 EDT Laser Photonics receives fourth order from North American truck manufacturer - Laser Photonics Corporation announced that it has received a fourth order from a major North American truck manufacturer for its CleanTech Handheld LPC-2000-CTHD laser system.

07:19 EDT Six Flags installs 12.37-megawatt solar project in Los Angeles - Six Flags announced the installation of a new 12.37-megawatt solar carport and energy storage system at Six Flags Magic Mountain in Los Angeles. The project will rank as the largest single-site commercial renewable energy project in California and largest solar project allocated toward a for-profit organization in the United States, distinguishing Six Flags as a leader in the industry.

07:18 EDT Draganfly delivers second situational awareness drone to Ukraine - Draganfly announces the second delivery of Draganfly situational awareness drones to DSNS Emergency Services Ukraine, Cherkasy office, through Firefighter Aid Ukraine. This delivery follows Draganfly's initial delivery to the DSNS Kyiv office as part of an initiative to provide Draganfly's technology across DSNS regional offices to assist with emergency response and landmine mapping operations throughout Ukraine. "We are deeply honored to provide our technology to support critical operations in Ukraine, including humanitarian and landmine operations," said Cameron Chell, President and CEO of Draganfly. "We recognize the urgency and gravity of these challenges, and we are proud to provide our technology to aid in mitigating the impact of these issues. These drones are important for enhancing situational awareness, ensuring the safety of Ukraine personnel with a tactical advantage in the field to effectively manage the ongoing conflict."

07:16 EDT Alkermes receives second interim award in Janssen arbitration - Alkermes (ALKS) announced that on April 19 it received a second interim award from the arbitral tribunal in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica, a subsidiary of Johnson & Johnson (JNJ). Pursuant to the Second Interim Award: Back royalties related to FY22 of approximately $194M, inclusive of interest, are due to Alkermes from Janssen under the two agreements; and a separate Know-How Royalty term applies for each of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA, as follows: The term for INVEGA SUSTENNA ends on Aug. 20, 2024; The term for INVEGA TRINZA ends in the Q2 of 2030; The term for INVEGA HAFYERA ends in May 2030; Royalties for CABENUVA in the U.S. are owed until Dec. 31, 2036. The Tribunal directed the parties to confer and advise within 21 days concerning the rate of interest and proposed further proceedings, including whether any issues remain for resolution by the Tribunal prior to the Tribunal's issuance of a final award.

07:15 EDT PandoLogic introduces pandoDIVERSITY recruitment solution - PandoLogic announced that its latest innovation, pandoDIVERSITY, will launch at this week's UNLEASH Conference in Las Vegas. Designed to help customers attract and recruit underrepresented job candidates, pandoDIVERSITY uniquely supports diversity recruitment goals.

07:15 EDT Mueller Industries boosts dividend by 20% to 30c per share - Increased the quarterly dividend by 20% to $.30 per share

07:14 EDT Halliburton CEO says outlook 'is strong' - "Halliburton's performance in the first quarter again demonstrated the earnings power of our strategy, the strength of our competitive position globally and execution for our customers. Total company revenue increased 33% and operating income grew 91% compared to the first quarter of 2022. Both of our divisions delivered strong margin performance," commented Jeff Miller, Chairman, President and CEO. "My Halliburton outlook -- for both the current year and the long-term -- is strong. We hear it from our customers, and we see it in our first quarter results. Our customers are clearly motivated to produce more oil and gas and service capacity is tight. Our strong execution culture, differentiated technology portfolio, and collaborative approach with customers - drive margin improvements and growth across our business. I am confident that we will execute our strategic priorities and deliver shareholder returns. I expect the execution of our strategy will deliver significant and growing free cash flow generation for Halliburton," concluded Miller.

07:13 EDT Mercury Systems hosts U.S. Senator Sinema at Phoenix facility - Mercury Systems on Friday hosted U.S. Sen. Kyrsten Sinema and a group of manufacturing business leaders for an event at its Phoenix facility. The event, organized by the Arizona Manufacturers Council and the National Association of Manufacturers, focused on U.S. manufacturing competitiveness and workforce. Sen. Sinema led a roundtable discussion around policies needed to ensure workforce availability for critical domestic aerospace and defense manufacturers. "Mercury was delighted to host Senator Sinema and global technology manufacturing leaders for this important conversation," said Tom Smelker, Mercury's Vice President and General Manager of Microsystems. "The vast majority of advanced semiconductor packaging is done in southeast Asia today, and the United States recognizes the need for more secure domestic capacity. But our skilled labor workforce is constrained, and we need a faster path to bring in more talent."

07:12 EDT Century Aluminum to acquire 55% interest in Jamalco Alumina Refinery - Century Aluminum announced that it has entered into an agreement with Noble Group Holdings to acquire Noble's 55% ownership interest in Jamalco, a bauxite mining and alumina production joint venture in Jamaica. Pursuant to the terms of the agreement, a wholly owned subsidiary of Century will acquire General Alumina Holdings Limited, a Noble subsidiary and owner of Noble's 55% interest in Jamalco, for $1. The transaction is expected to close by the end of April 2023. "This acquisition is highly strategic for Century as it secures a predictable, long-term supply of alumina, our most critical raw material and achieves increased transparency and control of our supply chain," said Jesse Gary, President and CEO of Century. "Acquiring this interest in Jamalco allows us to integrate our aluminum smelting operations with this critical upstream supply of bauxite and alumina to create a more balanced and robust operational footprint, resulting in an organization that is better positioned to deliver strong performance through industry cycles.

07:11 EDT Asensus Surgical: Fukuoka Tokushukai Hospital in Japan to use Senhance - Asensus Surgical announced that Fukuoka Tokushukai Hospital in Kasuga City, Japan has entered into an agreement to lease and utilize a Senhance Surgical System.

07:10 EDT JetBlue reports Q1 revenue passenger miles 13.4B up 22% - Reports Q1 available seat miles 16.769B, up 9%.

07:09 EDT First Wave BioPharma exceeds 50% enrollment target for Phase 2 SPAN trial - First Wave BioPharma announced that it has now surpassed the 50% enrollment target in its ongoing Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency, EPI, in patients with cystic fibrosis, CF. The Phase 2 multi-center clinical trial is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve patients. The primary efficacy endpoint is the coefficient of fat absorption, with secondary endpoints of stool weight, signs and symptoms of malabsorption and coefficient of nitrogen absorption. Topline results from the study are anticipated by mid-2023. James Sapirstein, Chief Executive Officer of First Wave BioPharma, commented, "We are very pleased to have reached the half-way mark of enrollment in our SPAN study of adrulipase. This represents an important milestone for First Wave and demonstrates that we are on track to complete enrollment in 1H'23 and report topline data in July 2023. Once again, we would like to thank both the participating patients and our clinical collaborators for ensuring successful study progression."

07:06 EDT Invivyd announces FDA has cleared IND application for VYD222 - Invivyd announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug, IND, application for VYD222, a monoclonal antibody candidate. Invivyd is developing VYD222 for the prevention of COVID-19 in vulnerable populations, such as immunocompromised people. "We are pleased that the FDA has cleared our IND for VYD222 and we are excited by the progress we've made in our ongoing Phase 1 VYD222 clinical trial," said Dave Hering, chief executive officer of Invivyd. "We have completed dosing of the first cohort and have moved to the second dosing cohort, with initial readouts from the Phase 1 clinical trial on track for the second quarter. The swift progress of our Phase 1 VYD222 clinical trial, along with the FDA's recent clearance of the VYD222 IND, are important steps in our plan to rapidly advance a stream of mAb candidates designed to keep pace with SARS-CoV-2 viral evolution."

07:05 EDT Green Thumb Industries announces official Dead & Copany after-party - Green Thumb Industries announced the upcoming official Dead & Company after-party in Chicago, featuring rising artist LP Giobbi. Presented by RYTHM, the nation's leading premium cannabis brand, the after-party will take place on Friday, June 9th at the Metro on Clark Street, which is close to Wrigley Field in Chicago. Tickets can be purchased at lpgiobbi.com. The after-party will follow Dead & Company's Friday night performance at Wrigley Field, with a portion of proceeds from the event supporting Femme House. Femme House was co-founded by Giobbi to help foster more equitable opportunities in the music industry for women and gender-expansive individuals.

07:04 EDT ALX Oncology enters clinical trial collaboration with Sanofi - ALX Oncology Holdings announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA, Sanofi's monoclonal antibody that targets a specific epitope on the CD38 receptor on multiple myeloma cells, for the treatment of patients with relapsed or refractory multiple myeloma. SARCLISA is approved in multiple countries, including the U.S., in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received greater than 2 prior therapies. SARCLISA is also approved in multiple countries in combination with carfilzomib and dexamethasone for the treatment of patients with RRMM who have received 1-3 prior lines of therapy and in the E.U. for patients with multiple myeloma who have received at least 1 prior therapy. Under the terms of the agreement, Sanofi will conduct a Phase 1/2 study to evaluate the safety, efficacy, pharmacokinetics and biomarker data of evorpacept in combination with SARCLISA and dexamethasone in patients with RRMM. Part 1 will evaluate dosing of evorpacept in combination with standard doses of SARCLISA and dexamethasone to identify a recommended dose. Part 2 will investigate the efficacy and safety of this combination in an expanded population of patients with RRMM. ALX Oncology will supply evorpacept and Sanofi will supply SARCLISA for this study.

07:02 EDT Stablix, Vertex collaborate for targeted protein stabilization therapeutics - Stablix announced a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated focused on discovering and developing novel RESTORAC small molecules for TPS. Under the terms of the agreement, Stablix will apply its proprietary platform toward the discovery of novel heterobifunctional small molecule drug candidates gainst specified targets involved in multiple diseases. Vertex will receive an exclusive license to certain molecules identified under the collaboration and will be solely responsible for development and commercialization. Stablix will receive an upfront payment including a convertible note investment and is eligible for research, development, regulatory and commercial milestones, plus tiered royalties on future net sales on any products that may result from the collaboration. Vertex will be responsible for all research costs associated with the collaboration.

06:57 EDT Verizon reports Q1 total broadband net additions of 437,000 - Total broadband net additions of 437,000 was the largest result in more than a decade, reflecting a strong demand for fixed wireless and Fios products. This result included 393,000 fixed wireless net additions, an increase from 379,000 fixed wireless net additions in fourth-quarter 2022. 67,000 Fios Internet net additions, an increase from 60,000 Fios Internet net additions in first-quarter 2022. Total wireless service revenue of $18.9 billion, a 3.0 percent increase year over year. Postpaid phone net losses of 127,000, and retail postpaid net additions of 633,000. Total wireless postpaid phone gross additions increased 5.3 percent year over year, primarily driven by an 11.5 percent year over year growth in Consumer phone gross additions. Total retail postpaid churn of 1.15 percent, and retail postpaid phone churn of 0.90 percent.

06:49 EDT MSCI sees FY23 Adjusted EBITDA Expense $965M-$995M - Sees FY23 Operating Expense $1.090B-$1.130B; Interest Expense including amortization of financing fees $184M-$187M; Depreciation & Amortization Expense $125M-$135M; CapEx $75M-$85M; Net Cash Provided by Operating Activities $1.145B-$1.195B; and Free Cash Flow $1.060-$1.120M.

06:45 EDT 3M announces restructuring actions, to reduce 6,000 positions globally - 3M is taking restructuring actions. The structural reorganization will reduce the size of the corporate center of the company, simplify supply chain, streamline 3M's geographic footprint, reduce layers of management, and further align business go-to-market models to customers. These restructuring actions are expected to affect all functions, businesses, and geographies and will impact approximately 6,000 positions globally, in addition to the reduction of 2,500 global manufacturing roles announced in January. 3M anticipates annual pre-tax savings of $700M to $900M upon completion of these actions. These actions are expected to reduce costs and drive long-term improvement in margins and cash flow while enabling a more efficient and effective structure for driving long-term growth. The company will continue to focus its commercial efforts in high-growth markets including automotive electrification, home improvement, personal safety, electronics, and health care. In addition, 3M will prioritize emerging growth areas such as climate technology, sustainable packaging, industrial automation, semiconductors, and next-generation consumer electronics. The company expects total pre-tax charges of $700M to $900M inclusive of previous actions announced in January. 3M expects to incur approximately half of the pre-tax charges in 2023, with $175M to $250M expected in the second quarter. The charges will be offset by pre-tax savings and are included in the company's full-year 2023 guidance.

06:37 EDT PepsiCo: Businesses have remained 'resilient' - In prepared commentary ahead of its quarterly earnings conference call, PepsiCo said it expects its North America beverage and convenient foods businesses to remain resilient and its international markets to perform well despite continued geopolitical and economic volatility and uncertainty. PepsiCo said it remains committed to investing appropriately in its business, paying, and growing the annual dividend, selectively considering acquisitions, partnerships and divestitures.

06:32 EDT Xerox sees FY23 Revenue growth flat to down low-single-digits - Sees FY23 revenue growth flat to down low-single-digits in constant currency; adjusted operating Margin 5.0%-5.5%; free cash flow at least $500M.

06:25 EDT Dow Inc. selects Linde as industrial gas partner for clean hydrogen, nitrogen - Dow (DOW) announced it has selected Linde (LIN) as its industrial gas partner for the supply of clean hydrogen and nitrogen for its proposed net-zero carbon emissions integrated ethylene cracker and derivatives site in Fort Saskatchewan, Alberta, Canada. Final investment decisions for both the Dow and Linde projects are subject to approval by both companies' respective board of directors and various regulatory agencies. Final investment decisions are expected in fourth quarter this year for a potential startup of phase 1 in 2027. Under the parties' framework agreement, Linde will complete the design and engineering for a Linde-owned and operated world-scale air separation and autothermal reformer complex. This complex would be integrated with Linde's existing operations in Fort Saskatchewan.

06:25 EDT General Electric sees FY23 Aerospace organic revenue growth mid to high teens - Sees FY23 Aerospace operating profit $5.3B-$5.7B, with free cash flow "up." Sees FY23 Vernova Renewable Energy organic revenue growth up mid single digits, with "significantly better" operating profit and free cash flow flat to improving. Sees FY23 Vernova Power organic revenue growth mid single digits, with slightly better operating profit and lower free cash flow. Comments taken from Q1 earnings conference call presentation slides.

06:21 EDT Danaher sees FY23 base business core revenue up mid-single digits - The company said, "For the second quarter and full year 2023, the Company anticipates that non-GAAP base business core revenue growth will be up mid-single digits year-over-year."

06:20 EDT UBS says client activity levels 'could remain subdued' in Q2 - The company said, "Persistently high inflation and tight labor markets in many countries in the first quarter of 2023 caused central banks to continue to raise interest rates. The recent liquidity concerns in the banking sector and geopolitical tensions, particularly between the US and China and with regard to the Russia-Ukraine war, led to significant uncertainty in asset valuations and the outlook for economic growth. Against this backdrop, clients continued to diversify cash holdings by investing their deposits into money market instruments, while sentiment and activity levels remained muted in the first quarter of 2023. The macroeconomic situation going forward remains uncertain, and while concerns about the stability of banks have abated, they have not gone away. As a result, client activity levels could remain subdued in the second quarter of 2023. Weak client sentiment may affect net new assets in our asset-gathering businesses; however, we expect net interest income will remain at higher levels, compared with last year, in the current interest rate environment. We are focused on completing the acquisition of Credit Suisse, most likely in the second quarter of 2023 which will advance our strategy, particularly in Global Wealth Management and Switzerland. The complexity of the integration will require sustained diligent effort. While we execute these changes, we will not be distracted from our primary focus: supporting our clients with advice and solutions."

06:16 EDT Assertio to acquire Spectrum in all-stocl and CVR transaction - Assertio Holdingsa (ASRT) and Spectrum Pharmaceuticals (SPPI) announced that they have entered into a definitive agreement pursuant to which Assertio will acquire all outstanding shares of Spectrum in an all-stock and contingent value rights, or CVR, transaction. Under the terms of the agreement, at closing, Spectrum stockholders will receive a fixed exchange ratio of 0.1783 shares of Assertio common stock for each share of Spectrum common stock they own, implying an upfront value of $1.14 per Spectrum share, or approximately $248M, based on Assertio's stock price on April 24 and an initial 65% premium to Spectrum's closing price on such date. Additionally, Spectrum stockholders will receive one CVR per Spectrum share entitling them to receive up to an additional 20c per share in total, or approximately $43M, payable in cash or stock at Assertio's election, for $1.34, or approximately $291M, a total potential premium of 94%. Subject to adjustments, each CVR shall represent the right to receive 10c payable upon ROLVEDON net sales achieving $175M during the calendar year ending December 31, 2024, and 10c payable upon ROLVEDON net sales achieving $225M during the calendar year ending December 31, 2025. Following the close of the transaction, Assertio stockholders will own approximately 65% of the combined company, and Spectrum stockholders will own approximately 35%, on a fully diluted basis. The transaction, which has been approved by the boards of directors of both companies, is expected to close in the Q3. Assertio intends to retain the majority of Spectrum's commercial team and add operating costs of approximately $60M annually. The remaining cost synergies are expected to accelerate and enhance the profit opportunities for the combined company and generate double-digit accretion to adjusted EPS and increased operating cash flow in 2024.

06:11 EDT Insulet announces FDA approval of Omnipod GO - Insulet announced the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. Insulet plans to commercialize Omnipod GO in the United States in 2024.

06:03 EDT Dow Inc. reports Q1 operating EPS 71c, consensus 36c - Reports Q1 revenue $11.85B, consensus $11.35B. Operating EPS excludes significant items in the quarter, totaling 71c per share, primarily due to restructuring costs and a litigation matter. Jim Fitterling, chairman and chief executive officer, commented on the quarter: "Team Dow demonstrated its agility and remained disciplined through challenging macroeconomic conditions - leveraging our structurally advantaged feedstock positions, focusing on higher-value products where demand remained resilient, and aligning our operating rates with market dynamics. Our actions to deliver $1 billion in cost savings in 2023 are progressing, reinforcing our low-cost-to-serve operating model and continuing to maximize cash flow generation. With ample liquidity and financial flexibility, execution of our strategy is on track as we advance our disciplined and balanced capital allocation priorities for long-term value creation."

05:38 EDT Coinbase files narrow action to seek clarity from SEC for crypto industry - Coinbase Chief Legal Officer Paul Grewal said in a blog post that the company on Monday filed a narrow action in the U.S. Circuit Court "to compel the SEC to respond 'yes or no' to a rulemaking petition we filed with them last July asking them to provide regulatory guidance for the crypto industry. The SEC is required by law to respond to petitions 'within a reasonable time,' but they have not yet responded to our petition from last July, which is why we filed our action in court today. It's obvious that there's a lack of clarity among our regulators regarding crypto, as even the chair of the SEC has declined to say which crypto assets are securities. The crypto industry, and its users need clear laws and rules to follow that are built for a new technology. Enforcement actions based in inapplicable securities law aren't the answer." Reference Link

05:18 EDT I-Mab receives arbitration award relating to Tracon CD73 antibody pact - I-Mab (IMAB) announced the outcome of its arbitration with Tracon Pharmaceuticals (TCON) relating to the collaboration agreement to co-develop I-Mab's proprietary CD73 antibody, uliledlimab and the collaboration agreement to potentially co-develop I-Mab's bi-specific antibodies. The arbitration award concluded the multi-year long dispute between I-Mab and Tracon. The award determined that the TJD5 Agreement has been terminated for a pre-agreed termination fee of $9M plus interest payable by I-Mab pursuant to the original TJD5 Agreement, and, therefore Tracon has no rights to share any future economics with I-Mab. The arbitration award completely denied Tracon's groundless damages claim of over $200M for any breach under the BsAb Agreement and awarded no damages to Tracon. The Tribunal also confirmed the termination of the BsAb Agreement. Based on the arbitration award, I-Mab will bear a portion of Tracon's legal fees and costs, totaling approximately $13.5M. The resolution is crucial for I-Mab to preserve and further realize the value of uliledlimab and the bi-specific antibody portfolio through accelerating clinical development and on-going global partnership discussions. With these matters resolved, I-Mab is now in a position to accelerate the development and global partnership for uliledlimab and bi-specific antibody assets, which have the potential to create substantial value for the Company as soon as early 2024. This arbitration award is final and binding on the parties, and I-Mab intends to pursue confirmation of the award promptly.

05:09 EDT General Motors, Samsung SDI to invest over $3B to build U.S. battery cell plant - General Motors and Samsung SDI announced they plan to invest more than $3B to build a new battery cell manufacturing plant in the United States that is targeted to begin operations in 2026. The plant will have more than 30 GWh of capacity and will bring GM's total U.S. battery cell capacity to about 160 GWh when it is at full production. The companies plan to jointly operate the facility, and it is projected to have production lines to build nickel-rich prismatic and cylindrical cells. GM and Samsung SDI are not announcing the location of the plant or employment projections at this time, however, the number of new jobs in construction and operations are expected to number in the thousands.